Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 87, Issue 3, Pages 605-613Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2021.10.030
Keywords
BRAF inhibitor; dabrafenib; encorafenib; granuloma; granulomatous reaction; melanoma treatment; sarcoidosis; vemurafenib
Categories
Ask authors/readers for more resources
BRAF inhibitors have shown promise as targeted therapy for malignancies with BRAF mutations, but can lead to granulomatous reactions. This review characterizes the spectrum of these reactions and proposes an approach for their investigation and management.
V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors have emerged as a promising targeted therapy for malignancies with BRAF mutations, particularly metastatic melanoma. However, granulomatous reactions (GRs), including sarcoidosis and sarcoid-like reactions, have been reported as a consequence of BRAF inhibition. It is important to adequately characterize these GRs, including cutaneous manifestations and systemic involvement, in order to guide investigations and management. A literature review was conducted to characterize the spectrum of GRs associated with BRAF inhibitors, identifying 55 reactions affecting 51 patients, with 37 reactions limited to cutaneous involvement. Further, a possible correlation with cancer response, mechanisms of granuloma formation, and a proposed workup and management approach for these GRs are presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available